Recce Pharmaceuticals (ASX:RCE) Operating Cash Flow per Share : A$-0.07 (TTM As of Dec. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Recce Pharmaceuticals Operating Cash Flow per Share?

Recce Pharmaceuticals's operating cash flow per share for the six months ended in Dec. 2024 was A$-0.03. Recce Pharmaceuticals's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2024 was A$-0.07.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -13.40% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was -24.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Recce Pharmaceuticals's Operating Cash Flow per Share or its related term are showing as below:

ASX:RCE' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -35.7 Med: -18.5 Max: 3.2
Current: -13.4

During the past 9 years, Recce Pharmaceuticals's highest 3-Year average Operating Cash Flow per Share Growth Rate was 3.20% per year. The lowest was -35.70% per year. And the median was -18.50% per year.

ASX:RCE's 3-Year OCF Growth Rate is ranked worse than
75.84% of 1221 companies
in the Biotechnology industry
Industry Median: 9.3 vs ASX:RCE: -13.40

Recce Pharmaceuticals Operating Cash Flow per Share Historical Data

The historical data trend for Recce Pharmaceuticals's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Recce Pharmaceuticals Operating Cash Flow per Share Chart

Recce Pharmaceuticals Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Operating Cash Flow per Share

Get a 7-Day Free Trial

-0.03

-0.05

-0.07

Recce Pharmaceuticals Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Operating Cash Flow per Share	Get a 7-Day Free Trial													-0.06	-0.01	-0.04	-0.04	-0.03

Competitive Comparison of Recce Pharmaceuticals's Operating Cash Flow per Share

For the Biotechnology subindustry, Recce Pharmaceuticals's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Recce Pharmaceuticals's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Recce Pharmaceuticals's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Recce Pharmaceuticals's Price-to-Operating-Cash-Flow falls into.

Save Embed

;

Save Embed

;

Recce Pharmaceuticals Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Recce Pharmaceuticals's Operating Cash Flow per Share for the fiscal year that ended in Jun. 2024 is calculated as

Operating Cash Flow per Share (A: Jun. 2024 )	=	Cash Flow from Operations (A: Jun. 2024 )	/	Shares Outstanding (Diluted Average) (A: Jun. 2024 )
	=	-13.009	/	178.803
	=	-0.07

Recce Pharmaceuticals's Operating Cash Flow per Share for the quarter that ended in Jun. 2024 is calculated as

Operating Cash Flow per Share (Q: Dec. 2024 )	=	Cash Flow from Operations (Q: Dec. 2024 )	/	Shares Outstanding (Diluted Average) (Q: Dec. 2024 )
	=	-6.924	/	231.199
	=	-0.03

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.07

Recce Pharmaceuticals Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Recce Pharmaceuticals's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Recce Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Recce Pharmaceuticals Ltd (ASX:RCE) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

RECEF:USA R9Q:Germany

Address

180 George Street, Level 23, Salesforce Tower, Sydney, NSW, AUS, 2000

Website

https://www.recce.com.au

Recce Pharmaceuticals Ltd is an Australia-based globally-focused biotechnology company engaged in the development and commercialization of a new class of antibiotics. The company operates in only one business segment being research and development of pharmaceutical drugs. The firm operates in three geographic segments being Australia, the United Kingdom, and the United States of America, of which the majority of the revenue comes from Australia. The company offers antibiotic drugs to treat diseases caused by various bacteria namely Sepsis, Neisseria gonorrhoeaei, Escherichia coli, Mycobacterium abscessus, and others.

Recce Pharmaceuticals Headlines

No Headlines